Skip to main content
GLMD
NASDAQ Life Sciences

Galmed Pharmaceuticals Expands Aramchol Development into Cardiac Fibrosis via New Collaboration

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.573
Mkt Cap
$3.894M
52W Low
$0.411
52W High
$2.34
52W Position info
39% above low
Off High info
75% below high
Rel. Volume
Market data snapshot near publication time

GLMD sits 39% above its 52-week low of $0.411.

Summary

Galmed Pharmaceuticals announced a collaboration with Tissue Dynamics to develop a human-centered cardiac fibrosis platform, expanding the potential indications for its lead drug Aramchol into heart diseases.


Key Events · Product Development and Regulatory · GLMD

  • New Collaboration Announced

    Galmed Pharmaceuticals has partnered with Tissue Dynamics Ltd. to develop a human-centered chronic cardiac fibrosis platform.

  • Aramchol's Therapeutic Expansion

    The collaboration aims to advance Galmed's lead drug candidate, Aramchol, into complex fibrotic heart diseases, including post-MI remodeling and HFpEF, expanding its potential beyond liver and GI oncological indications.

  • Innovative Platform Development

    The platform will utilize advanced vascularized, sensor-embedded cardiac organoids with automation and AI to model chronic human cardiac fibrosis and accelerate drug discovery.


Analysis · GLMD · Life Sciences

Galmed Pharmaceuticals has announced a significant collaboration with Tissue Dynamics Ltd. to develop a novel platform for chronic cardiac fibrosis. This partnership is crucial as it expands the potential therapeutic applications of Galmed's lead drug candidate, Aramchol, into a new and substantial disease area: complex fibrotic heart diseases, including post-myocardial infarction remodeling and heart failure with preserved ejection fraction (HFpEF). For a clinical-stage biopharmaceutical company, broadening the indications for its primary asset can significantly enhance its long-term value proposition and market potential. The use of advanced human-centered organoid models with AI is an innovative approach that could accelerate drug discovery in this challenging field.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GLMD was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.41 to $2.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GLMD - Latest Insights

GLMD
Sep 08, 2026, 6:08 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.30
Real-time Price: $4.66 info
Change: +$0.360 (+8%) info
Market Cap: $4.822M info
GLMD
Sep 02, 2026, 4:20 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.12
Real-time Price: $4.66 info
Change: +$0.541 (+13%) info
Market Cap: $4.822M info
GLMD
Aug 19, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.513
Real-time Price: $4.66 info
Change: Reverse Stock Split info
Market Cap: $4.822M info
GLMD
Aug 17, 2026, 9:23 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.5145
Real-time Price: $4.66 info
Change: Reverse Stock Split info
Market Cap: $4.822M info
GLMD
Aug 17, 2026, 9:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.5206
Real-time Price: $4.66 info
Change: Reverse Stock Split info
Market Cap: $4.822M info